,Instrument,Enterprise Value to EBIT,Enterprise Value to EBITDA,Enterprise Value To Sales (Daily Time Series Ratio),Price / EPS (SmartEstimate Â®),Price To Book Value Per Share (Daily Time Series Ratio),Price To Cash Flow Per Share (Daily Time Series Ratio),TR.PRICECLOSE/TR.FreeOperatingCashFlowperShareAvgDilutedSharesOut,TR.VOLATILITY260D/100,TR.RETURNONAVGTOTEQTYPCTNETINCOMEBEFOREEXTRAITEMS/100,TR.ROATOTALASSETSPERCENT/100,TR.GROSSMARGIN/100,TR.NETINCOME/TR.Revenue,TR.LTDEBTTOTTLEQTYPCT/100,TR.LTDEBTTOTTLCAPITALPCT/100,Interest Coverage Ratio,Business Description,Business Description,Organization Founded Year,Number of Employees,Organization Website,Revenue,Company Market Cap,Net Income Reported - Mean,PERATIO,Price To Sales Per Share (Daily Time Series Ratio),Cost of Revenues - Total,Dividend yield,TR.F.DIVPAYOUTRATIOPCT/100
0,ZYDU.NS,14.4028027724956,11.330400194471,3.21054719711082,21.8180704489982,2.98499009900951,23.9413408009551,99.9643772411732,0.249963946168423,0.149480359697,0.090030785544,0.5906703,0.293956187930718,0.022247582296,0.016249403859,22.9842657343,"Zydus Lifesciences Ltd. is an India-based life sciences company. The Company is engaged in the research and development, manufacturing, marketing and selling of finished dosage human formulations, such as generics and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients (APIs); animal healthcare products, and consumer wellness products. Its products include Bilypsa (saroglitizar), Oxemia (desidustat), Ujvira (biosimilar Kadcyla), and Exemptia. It offers Bilypsa drug for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Desidustat is an oral, small molecule hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor, which is used for the treatment of anemia in chronic kidney disease (CKD) patients. It is also developing an oral small molecule ZYIL1, targeted at selectively suppressing inflammation caused by the NLRP3 inflammasome. Its ZyCoV-D is a plasmid deoxyribonucleic acid (DNA) vaccine for COVID-19.","Zydus Lifesciences Ltd. is an India-based life sciences company. The Company is engaged in the research and development, manufacturing, marketing and selling of finished dosage human formulations, such as generics and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients (APIs); animal healthcare products, and consumer wellness products. Its products include Bilypsa (saroglitizar), Oxemia (desidustat), Ujvira (biosimilar Kadcyla), and Exemptia. It offers Bilypsa drug for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Desidustat is an oral, small molecule hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor, which is used for the treatment of anemia in chronic kidney disease (CKD) patients. It is also developing an oral small molecule ZYIL1, targeted at selectively suppressing inflammation caused by the NLRP3 inflammasome. Its ZyCoV-D is a plasmid deoxyribonucleic acid (DNA) vaccine for COVID-19.",1995,23743,https://www.zyduslife.com/zyduslife/,152652000000,498033885017.19,22503034520,21.38,3.03945059790619,69615000000,0.508595259892178,0.159845605817273
